Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
J&J Seeks Approval Of TB Drug
by Lisa M. Jarvis
July 9, 2012
| A version of this story appeared in
Volume 90, Issue 28
Janssen Research & Development, an arm of Johnson & Johnson, has filed a New Drug Application for bedaquiline, an antibiotic to be used in a combination regimen to treat multi-drug-resistant tuberculosis (MDR-TB). If approved, the diarylquinoline will be the first TB compound with a new mechanism of action in more than 40 years. Approval would also bring J&J a priority review voucher, a certificate that companies developing drugs against neglected diseases can use to speed up FDA review of another drug.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter